Radius Health's (RDUS) average rating among analysts is a buy, with an average price target of $38. Price: 25.95, Change: +1.05, Percent Change: +4.22 ...
Radius Health's (RDUS) average rating among analysts is a buy, with an average price target of $40. Price: 21.69, Change: +0.47, Percent Change: +2.19 ...
Kurt Graves, Director, reported a sale of 4,800 shares in Radius Health (RDUS) on Apr 16, 2019, for $107,136. Following the Form 4 filing with the SEC,...
Dr Debasish Roychowdhury, Director, reported a sale of 4,800 shares in Radius Health (RDUS) on Apr 11, 2019, for $106,320. After the Form 4 filing with...
| Address | 950 Winter Street Waltham, Massachusetts 02451 |
| Phone | +1.617.551.4000 |
| Number of Employees | 398 |
| Recent SEC Filing | 08/07/2019 10-Q |
| President, Chief Executive Officer& Director | Jesper Høiland |
| CFO, Treasurer, Principal Accounting Officer & SVP | Jose Carmona |
| Chief Medical Officer | Charles Q. Morris |
| Vice President-Technical Operations | Chhaya Shah |
| Price Open | $28.25 |
| Previous Close | $29.02 |
| 52 Week Range | $12.81 - 29.68 |
| Market Capitalization | $1.3 B |
| Shares Outstanding | 46.1 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 11/07/2019 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$3.69 |
| Beta vs. S&P 500 | N/A |
| Revenue | $99.2 M |
| Net Profit Margin | -127.22% |
| Return on Equity | -368.58% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
